Search Results

Search Results

Showing 1-9 of 9 Resources
  • Efficacy of a Treatment for Chronic Myeloid Leukemia

    Efficacy of a Treatment for Chronic Myeloid Leukemia

    Data Point

    Dr. Brian Druker and colleagues monitored white blood cell counts in six patients with chronic myeloid leukemia treated with the drug, STI571, which blocks the activity of the cancer-causing tyrosine kinase BCR-ABL.

  • BCR-ABL: Cancer Protein Structure and Function

    BCR-ABL: Cancer Protein Structure and Function

    Click & Learn

    This Click and Learn describes how understanding the structure of the BCR-ABL kinase led to the development of an effective treatment for chronic myeloid leukemia.

  • Gleevec-resistant BCR-ABL: ABL Kinase Domain

    Gleevec-resistant BCR-ABL: ABL Kinase Domain

    3D Model

    A 3D model of gleevec-resistant BCR-ABL, a mutated form of BCR-ABL.

  • BCR-ABL: ABL Kinase Domain

    BCR-ABL: ABL Kinase Domain

    3D Model

    A 3D model of BCR-ABL, an unregulated kinase that causes cancer.

  • Cancer As a Genetic Disease

    Cancer As a Genetic Disease

    Lecture

    (58 min 33 sec) Understanding that cancer is caused by mutations in genes that regulate cell proliferation has led to the development of targeted drug therapies.

  • Gleevec-Resistant Form of Kinase BCR-ABL

    Gleevec-Resistant Form of Kinase BCR-ABL

    Animation

    (2 min 14 sec) Mutations in the BCR-ABL gene can cause resistance to Gleevec, but another drug, dasatinib, can be used instead.

  • Gleevec Inhibits Cancer-Causing Kinase BCR-ABL

    Gleevec Inhibits Cancer-Causing Kinase BCR-ABL

    Animation

    (3 min 31 sec) The drug Gleevec binds to and inactivates BCR-ABL, a mutant kinase that causes chronic myeloid leukemia. 

  • Gleevec

    Gleevec

    Animation

    (1 min 4 sec) Gleevec is a drug designed to interfere with the stimulation of growth in leukemia cells. This 3D animation shows how this is achieved.

  • CML and Gleevec

    CML and Gleevec

    Animation

    (41 sec) Chronic myeloid leukemia (CML) is caused by a mutation that leads to an abnormal protein that is always active. The drug Gleevec has a shape that fits into the active site of the abnormal protein and stops its harmful effects.